Yasuhiro Hamada

Yasuhiro Hamada

Auto-generated profile, based on publicly available information

Yasuhiro Hamada

Department of Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kagawa, 761-0793, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014
Verified
Conference Paper
Closed access
MAMasato Akagi
Masato Akagi
XHXiao Han
Xiao Han
REReda Elsaid Elbarougy
Reda Elsaid Elbarougy
YHYasuhiro Hamada
Yasuhiro Hamada
JLJunfeng Li
Junfeng Li
Speech-to-speech translation (S2ST) is the process by which a spoken utterance in one language is used to produce a spoken output in another language. The conventional approach to S2ST has focused on processing linguistic information only by directly translating the spoken utterance from the source language to the target language without taking into account par-alinguistic and non-linguistic information such as the emotional states at play in the source language. This paper introduces activities of JAIST AIS lab1 that explore how to deal with para- and non-linguistic information among multiple languages, with a particular focus on speakers' emotional states, in S2ST applications called "affective S2ST". In our efforts to construct an effective system, we discuss (1) how to describe emotions in speech and how to model the perception/production of emotions and (2) the commonality and differences among multiple languages in the proposed model. We then use these discussions as context for (3) an examination of our "affective S2ST" system in operation.

23 June 2011 in Cold Regions Science and Technology
Verified
Journal Article
Closed access
YHYasuhiro Hamada
Yasuhiro Hamada
TNTsutomu Nagata
Tsutomu Nagata
HKHideki Kubota
Hideki Kubota
TOTakayuki Ono
Takayuki Ono
YHYoshiaki Hashimoto
Yoshiaki Hashimoto

29 March 2024 in Heliyon
Verified
Journal Article
Open access
YHYasuhiro Hamada
Yasuhiro Hamada
TTTadayuki Takata
Tadayuki Takata
HIHisakazu Iwama
Hisakazu Iwama
RKRie Kawakita
Rie Kawakita
WNWakako Nonaka
Wakako Nonaka
TMTsutomu Masaki
Tsutomu Masaki
Neuroprotective therapeutic potential for restoring dysregulated microRNA (miRNA) expression has previously been demonstrated in a gerbil cerebral infarction model. However, since temporal changes in miRNA expression profiles following stroke onset are unknown, miRNAs proving to be useful therapeutic targets have yet to be identified. We evaluated cognitive function, hippocampal neuronal cell death, and microarray-based miRNA expression profiles at 5, 9, 18, 36, and 72 h after 5-min whole brain ischemia in gerbils. A decline in cognitive function occurred in parallel with increased neuronal cell death 36–72 h after ischemia. The Jonckheere-Terpstra test was used to analyze miRNA expression trends 5–72 h after ischemia. The expression levels of 63 miRNAs were significantly upregulated, whereas 32 miRNAs were significantly downregulated, monotonically. Of the 32 monotonically downregulated miRNAs, 18 showed the largest decrease in expression 5–9 h after ischemia. A subset of these dysregulated miRNAs (miR-378a-5p, miR-204-5p, miR-34c-5p, miR-211-5p, miR-34b-3p, and miR-199b-3p) could be associated with brain ischemia and neuropsychiatric disorders.

8 January 2024 in Neurology and Clinical Neuroscience
Verified
Journal Article
Open access
YHYasuhiro Hamada
Yasuhiro Hamada
KDKazushi Deguchi
Kazushi Deguchi
KTKeita Takaba
Keita Takaba
RKRie Kawakita
Rie Kawakita
TTTadayuki Takata
Tadayuki Takata
TMTsutomu Masaki
Tsutomu Masaki
Background: A realistic treatment goal for myasthenia gravis (MG) is achieving minimal manifestations or better status with prednisolone at ≤5 mg/day (MM‐or‐better‐5 mg), considering a patient's health‐related quality of life. Prognosis prediction during the early phases of immunotherapies might be critical for determining subsequent treatment strategies; however, the appropriate biomarkers remain unknown.Aim: This study aimed to clarify whether the reduction rate of anti‐acetylcholine receptor antibody (RR‐AChR Ab) titer levels is a useful biomarker for predicting MM‐or‐better‐5 mg achievement.Methods: We retrospectively investigated patients with MG and AChR Abs who received immunotherapy for the first time. The RR‐AChR Ab titer levels were calculated in the early (within 30 days), middle (31–60 days), and late (61–100 days) periods after starting immunotherapies. A receiver operating characteristic (ROC) curve was generated to determine an appropriate cutoff value for RR‐AChR Abs to achieve an MM‐or‐better‐5 mg.Results: Of 53 patients, 24 (45%) achieved MM‐or‐better‐5 mg after 1 year. For the early period, the RR‐AChR Ab cutoff value to predict MM‐or‐better‐5 mg was 1.68%/day with an area under the curve (AUC) of 0.75 (sensitivity, 85%; specificity, 70%). However, the middle and late posttreatment AUC values did not predict MM‐or‐better‐5 mg achievement.Conclusion: The RR‐AChR Ab might be an appropriate prognostic biomarker during the early period of MM‐or‐better‐5 mg achievement. In the era of early fast‐acting treatment strategies, the RR‐AChR Ab trend after starting immunotherapies may guide the subsequent treatment choices.

1 April 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
YCYuta Chiba
Yuta Chiba
TTTadayuki Takata
Tadayuki Takata
YHYasuhiro Hamada
Yasuhiro Hamada
WNWakako Nonaka
Wakako Nonaka
YKYohei Kokudo
Yohei Kokudo
TMTsutomu Masaki
Tsutomu Masaki